Clinical Pharmacokinetics

, Volume 5, Issue 5, pp 424–440 | Cite as

Monitoring Plasma Concentrations of Salicylate

  • M. Mandelli
  • G. Tognoni
Article

Abstract

Measurement of the plasma concentration of salicylate has been made in the majority of clinical settings where salicylates, mostly in the form of acetylsalicylic acid (aspirin), are used extensively to treat chronic rheumatic conditions. At the same time, studies on the kinetics of salicylates have increased in the specialised literature. Analysis of published papers suggests a surprising difference between principles documented in controlled situations and what happens in routine clinical practice. Recommended dosage regimens are based on a rather narrow amount of data, as relevant studies include few patients and have not used readily comparable protocols.

The wealth of information available on the kinetics and metabolism of salicylates has not yet produced generally accepted agreement on how to achieve optimum therapeutic results. Plasma concentration monitoring programmes aim mainly at avoiding side effects and checking compliance, but do not deal specifically with overall evaluation of therapeutic outcome. In the longer term, aspirin may possibly become less favoured as the initial drug of choice for the treatment of chronic rheumatic conditions, and the merits of monitoring plasma salicylate levels could be even less favoured. In the meantime, however, as clinical practice still largely involves use of aspirin, prospective collection of more controlled data on larger population groups seems warranted, not only for the benefit of treated patients but also for the purpose of assessing more thoroughly the clinical relevance of therapeutic drug monitoring in this area.

Keywords

Aspirin Salicylic Acid Salicylate Rheumatoid arthritIS Salicylic Acid Concentration 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abrishami, M.A. and Thomas, J.: Aspirin intolerance — A review. Annals of Allergy 39: 28–37 (1977).PubMedGoogle Scholar
  2. Ali, M.A. and Routh, J.I.: The protein binding of acetylsalicylic acid and salicylic acid, Clinical Chemistry 15: 1027–1038 (1969).PubMedGoogle Scholar
  3. Ali Laik, S.: A comparative study of the derivatization of salicylic acid and acetylsalicylic acid with BSTFA, MSTFA and methyl rodide in presence of potassium carbonate prior to GLC determination. Chromatografia 8: 33–34 (1975).CrossRefGoogle Scholar
  4. Ali, M.; McDonald, J.W.; Thiessen, J.J. and Coates, P.E.: Plasma acelylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin, Stroke 11: 9–13 (1980).PubMedCrossRefGoogle Scholar
  5. American Pharmaceutical Association: Evaluations of Drug Interactions, 2nd. ed, (APA, Washington, 1976).Google Scholar
  6. Ascione, P.P. and Chrekian, G.P.: Automated high-pressure liquid chromatographic analysis of aspirin, phenacetin, and caffeine. Journal of Pharmaceutical Sciences 64: 1029–1033 (1979).CrossRefGoogle Scholar
  7. Athreya, B.H.; Moser, G.; Cecil, H.S. and Myers, A.R.: Aspirin-induced hepatotoxicity in juvenile rheumatoid arthritis, A prospective study. Arthritis and Rheumatism 18: 347–352 (1975).PubMedCrossRefGoogle Scholar
  8. Bardare, M.; Chislaghi, G.U.; Mandelli, M. and Sereni, F.: Value of monitoring plasma salicylate levels in treating juvenile rheumatoid arthritis: observations in 42 cases. Archives of Disease in Childhood 53: 381–385 (1978).PubMedCrossRefGoogle Scholar
  9. Bedford, C.; Cummings, A.J. and Martin, B.K.: A kinetic study of the elimination of salicylate in man. British Journal of Pharmacology 24: 418–431 (1965).Google Scholar
  10. Bender, K.J.: Salicylate intoxication. Drug Intelligence and Clinical Pharmacy 9: 350–360 (1975).Google Scholar
  11. Berg, K.J.: Acute acetylsalicylic acid poisoning: Treatment with forced alkaline diuresis and diuretics. European Journal of Clinical Pharmacology 12: 111–116 (1977a).PubMedCrossRefGoogle Scholar
  12. Berg, K.J.: Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency. European Journal of Clinical Pharmacology 11: 111–116 (1977b).PubMedCrossRefGoogle Scholar
  13. Berg, K.J.: Acute effects of acetylsalicylic acid on renal function in normal man. European Journal of Clinical Pharmacology 11: 117–123 (1977c).PubMedCrossRefGoogle Scholar
  14. Bernstein, B.H.; Singsen, B.H.; King, K.K. and Hanson, V.: Aspirin-induced hepatotoxicity and its effect on juvenile rheumatoid arthritis. American Journal of Diseases of Children 131: 659–663 (1977).PubMedGoogle Scholar
  15. Bernstein, S.H. and Allerhand, J.: Abnormalities or serum proteins as criteria for the diagnosis of acute rheumatic fever. American Journal of Medical Sciences 247: 431–437 (1964).CrossRefGoogle Scholar
  16. Blair, D.; Rumack, B.H. and Peterson, R.G.: Analysis for salicylic acid in serum by high-performance liquid chromatography. Clinical Chemistry 24: 1543–1544 (1978).PubMedGoogle Scholar
  17. Borga, O.; Odar-Cederlöf, I.; Ringberger, V.-A. and Norlin, A.: Protein binding of salicylate in uremic and normal plasma. Clinical Pharmacology and Therapeutics 20: 464–475 (1976).PubMedGoogle Scholar
  18. Brown, S.S.; Cameron, J.C. and Matthew, H.: Plasma salicylate levels in acute poisoning in adults. British Medical Journal 2: 738–739 (1967).PubMedCrossRefGoogle Scholar
  19. Buchanan, N. and Rabinowitz, L.: Infantile salicylism — A reappraisal. Journal of Pediatrics 84: 391–395 (1974).PubMedCrossRefGoogle Scholar
  20. Calabro, J.J.; Burnstein, S.L. and Staley, H.L.: Letter to the Editor. Scandinavian Journal of Rheumatology 5: 251–252 (1976).PubMedCrossRefGoogle Scholar
  21. Cassell, S.; Furst, D.; Dromgoole, S. and Paulus, H.: Steady-state serum salicylate levels in hospitalized patients with rheumatoid arthritis. Arthritis and Rheumatism 22: 384–388 (1979).PubMedCrossRefGoogle Scholar
  22. Chiou, W. and Onyemelukwe, I.: Disintegration, dissolution and oral absorption in humans of five commercial buffered aspirin dosage form. Journal of Clinical Pharmacology 14: 597–603 (1974).PubMedGoogle Scholar
  23. Coldwell, B.B.; Solomonraj, G.; Boyd, E.M.; Jante, J. and Morrison, A.B.: The effect of dosage from and route of administration on the absorption and excretion of acetylsalicylic acid in man. Clinical Toxicology 2: 111–127 (1969).CrossRefGoogle Scholar
  24. Craig, J.O.; Ferguson, I.C. and Syme, J.: Infants, toddlers and aspirin. British Medical Journal 1: 757–761 (1966).PubMedCrossRefGoogle Scholar
  25. Cummings, A.J.; Martin, B.K. and Renton, R.: The elimination of salicylic acid in man: serum concentrations and urinary excretion rates. British Journal of Pharmacology 26: 461–467 (1966).Google Scholar
  26. Davies, M.G.; Vella Briffa, D. and Greaves, M.W.: Systemic toxicity from topically applied salicylic acid. British Medical Journal 1: 661 (1979).PubMedCrossRefGoogle Scholar
  27. Davison, C.: Salicylate metabolism in man. Annals of the New York Academy of Sciences 179: 249–268 (1971).PubMedCrossRefGoogle Scholar
  28. Davison, C. and Mandel, H.G.: Nonnarcotic analgesics and antipyretics, 1. Salicylates; in Di Palma (Ed.) Drill’s Pharmacology in Medicine, pp. 379–403 (McGraw-Hill, New York 1971).Google Scholar
  29. Davison, C. and Smith, P.K.: The binding of salicylic acid and related substances to purified proteins. Journal of Pharmacology and Experimental Therapeutics 133: 161–170 (1961).PubMedGoogle Scholar
  30. Day, R.; Shen, D. and Azarnoff, D.: Decline of steady-state serum salicylate in rheumatoid arthritis given high-dosage salicylate therapy. Clinical Pharmacology and Therapeutics 25: 220–221 (1979).Google Scholar
  31. Dick, W.C.; Gibson, R.; Gray, G.I.L. and Buchanan, W.W.: Salicylates and homeopathy. British Journal of Clinical Pharmacology 7: 530–531 (1979).Google Scholar
  32. Done, A.K.: Significance of measurements of salicylate in blood in case of acute ingestion. Pediatrics 26: 800–807 (1960).PubMedGoogle Scholar
  33. Done, A.K.: Salicylate, pharmacokinetics, and the Pediatrician. Pediatrics 54: 670–672 (1974).PubMedGoogle Scholar
  34. Doughty, R.A.; Gresecke, L. and Athreya, B.: Prospective study of salicylate therapy in juvenile rheumatoid arthritis. Dosage-serum salicylate levels and clinical/biochemical toxicity. Clinical Pharmacology and Therapeutics 25: 221 (1979).Google Scholar
  35. Edwards, L.J.: Dissolution and diffusion of aspirin in aqueous media. Trans Faraday Society 47: 1191–1210 (1951).CrossRefGoogle Scholar
  36. Ekstrand, R.; Alvan, G. and Borgå, O.: Concentration dependent plasma protein binding of salicylate in rheumatoid patients. Clinical Pharmacokinetics 4: 137–143 (1979).PubMedCrossRefGoogle Scholar
  37. Elliott, H.C.: Urinary excretion kinetics of salicyluric acid. Proceedings of the Society for Experimental Biology and Medicine 121: 861–864 (1966).PubMedGoogle Scholar
  38. Furst, D.E.; Gupta, N. and Paulus, H.E.: Evidence suggesting a genetic influence and induction of salicylurate formation. Journal of Clinical Investigation 60: 32–42 (1977).PubMedCrossRefGoogle Scholar
  39. Gibaldi, M.; Grundhofer, B. and Levy, G.: Time course and dose dependence of antacid effect on urine pH. Journal of Pharmaceutical Sciences 64: 2003–2004 (1975).PubMedCrossRefGoogle Scholar
  40. Gibson, T.; Zaphiropoulos, G.; Grove, J.; Widdop, B. and Berry, D.: Kinetics of salicylate metabolism. British Journal of Clinical Pharmacology 2: 233–238 (1975).PubMedCrossRefGoogle Scholar
  41. Gibson, R.G.; Gibson, S.L.M.; MacNeill, A.D.; Gray, G.H.; Dick, W.C. and Buchanan, W.W.: Salicylates and homeopathy in rheumatoid arthritis: preliminary observations. British Journal of Clinical Pharmacology 6: 391–395 (1978).PubMedCrossRefGoogle Scholar
  42. Graham, G.G.; Champion, G.D.; Day, R.O. and Pauli, P.D.: Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis. Clinical Pharmacology and Therapeutics 22: 410–420 (1977).PubMedGoogle Scholar
  43. Gunsberg, M.; Cham, B.E.; Imhoff, D.M.; Parsons, G.; Bochner, F. and Johnson, F.L.: Correlation of aspirin dose with concentrations of salicylic acid in plasma, plasma water and saliva and clinical response in patients with rheumatoid disease. Australian and New Zealand Journal of Medicine 10: 268–278 (1980).CrossRefGoogle Scholar
  44. Gupta, N.; Sarkissian, E. and Paulus, H.E.: Correlation of plateau serum salicylate level with rate of salicylate metabolism. Clinical Pharmacology and Therapeutics 18: 350–355 (1975).PubMedGoogle Scholar
  45. Harris, P.A. and Riegelman, S.: Acetylsalicylic acid hydrolysis in human blood and plasma. I. Methodology and in vitro studies. Journal of Pharmaceutical Sciences 56: 713–716 (1967).PubMedCrossRefGoogle Scholar
  46. Hill, J.B.: The effect of altering blood pH on rat tissue and plasma salicylate concentrations. Federation Proceedings 29: 434 proc. (1970).Google Scholar
  47. Hill, J.B.: Salicylate intoxication. New England Journal of Medicine 288: 1110–1113 (1973).PubMedCrossRefGoogle Scholar
  48. Hill, J.B. and Smith, R.M.: An automated microfluoromatic determination after salicylate in body fluids and tissue extracts. Biochemical Medicine 4: 24–35 (1970).PubMedCrossRefGoogle Scholar
  49. Hollister, L. and Levy, G.: Some aspects of salicylate distribution and metabolism in man. Journal of Pharmaceutical Sciences 54: 1126–1129 (1965).PubMedCrossRefGoogle Scholar
  50. Huston, G.: Salicylates and homeopathy. British Journal of Clinical Pharmacology 7: 529–530 (1979).PubMedCrossRefGoogle Scholar
  51. Jick, H. and Porter, J.: Drug-induced gastrointestinal bleeding. Lancet 2: 87–89 (1978).PubMedCrossRefGoogle Scholar
  52. Klinenberg, J.R. and Miller, F.: Effect of corticosteroids on blood salicylate concentration. Journal of the American Medical Association 194: 601–604 (1965).PubMedCrossRefGoogle Scholar
  53. Kramer, E, and Routh, J.I.: The binding of salicylic acid and acetylsalicylic acid to human serum albumin. Clinical Biochemistry 6: 98–105 (1973).PubMedCrossRefGoogle Scholar
  54. Kucera, J.L. and Bullock, F.J.: The binding of salicylate to plasma protein from several animal species. Journal of Pharmacy and Pharmacology 21: 293–296 (1969).PubMedCrossRefGoogle Scholar
  55. Lainhaw, D.A.: Rheumatoid arthritis improved by treatment with levamisole and L-histoline. Medical Journal of Australia 2: 382–385 (1976).Google Scholar
  56. Leonards, J.R.: The influence of solubility on the rate of gastrointestinal absorption of aspirin. Clinical Pharmacology and Therapeutics 4: 476–479 (1963).PubMedGoogle Scholar
  57. Leonards, J.R. and Levy, C.: Absorption and metabolism of aspirin administered in enteric coated tablets. Journal of American Medical Association 193: 99–104 (1965).CrossRefGoogle Scholar
  58. Levy, G.: Salicylurate formation — demonstration of Michaelis-Menten kinetics in man. Journal of Pharmaceutical Sciences 54: 496 (1965a).PubMedCrossRefGoogle Scholar
  59. Levy, G.: Comparison of dissolution and absorption rates of different commercial aspirin tablets. Journal of Pharmaceutical Sciences 50: 388–392 (1961).PubMedCrossRefGoogle Scholar
  60. Levy, G.: Effect of certain tablet formulation factors on dissolution rate of the active ingredient. I. Journal of Pharmaceutical Sciences 52: 1039–1046 (1963).PubMedCrossRefGoogle Scholar
  61. Levy, G.: Pharmacokinetics of salicylate elimination in man. Journal of Pharmaceutical Sciences 54: 959–967 (1965b).PubMedCrossRefGoogle Scholar
  62. Levy, G. and Garrettson, L.K.: Kinetics of salicylate elimination by newborn infants of mothers who ingested aspirin before delivery. Pediatrics 53: 201–210 (1974).PubMedGoogle Scholar
  63. Levy, G. and Giacomini, K.M.: Rational aspirin dosage regimens. Clinical Pharmacology and Therapeutics 23, 247–252 (1978).PubMedGoogle Scholar
  64. Levy, G. and Gumlow, R.H.: Effect of certain tablet formulation factors on dissolution rate of active ingredients. III. Tablet lubricants. Journal of Pharmaceutical Sciences 52: 1139–1144 (1963).PubMedCrossRefGoogle Scholar
  65. Levy, G. and Hollister, L.E.: Inter- and intrasubject variations in drug absorption kinetics. Journal of Pharmaceutical Sciences 53: 1446–1452 (1964).PubMedCrossRefGoogle Scholar
  66. Levy, G. and Leonards, J.R.: Absorption, metabolism and excretion of salicylates: in Smith and Smith (Eds.) The Salicylates: A critical bibliographic review. pp.5–48 (Interscience, New York 1966).Google Scholar
  67. Levy, G. and Tsuchiya, T.: Salicylate accumulation kinetics in man. New England Journal of Medicine 287: 430–432 (1972).PubMedCrossRefGoogle Scholar
  68. Levy, G. and Tsuchiya, T.: Effect of activated charcoal on aspirin absorption in man. I. Clinical Pharmacology and Therapeutics 13: 317–322 (1972b).PubMedGoogle Scholar
  69. Levy, G. and Yaffe, S.J.: The study of salicylate pharmacokinetics in intoxicated infants and children. Clinical Toxicology 1: 409–424 (1968).CrossRefGoogle Scholar
  70. Levy, G. and Yaffe, S.J.: Relationship between dose and apparent volume of distribution of salicylate in children. Pediatrics 54: 713–717 (1974).PubMedGoogle Scholar
  71. Levy, G.; Amsel, L.P. and Elliott, H.C.: Kinetics of salicyluric acid elimination in man. Journal of Pharmaceutical Sciences 58: 827–829 (1969a).PubMedCrossRefGoogle Scholar
  72. Levy, G.; Procknal, J.A. and Garrettson, L.K.: Distribution of salicylate between neonatal and maternal serum at diffusion equilibrium. Clinical Pharmacology and Therapeutics 18: 210–214 (1975a).PubMedGoogle Scholar
  73. Levy, O.; Vogel, A.W. and Amsel, L.P.: Capacity-limited salicylurate formation during prolonged administration of aspirin to healthy human subjects. Journal of Pharmaceutical Sciences 58: 503–504 (1969b).PubMedCrossRefGoogle Scholar
  74. Levy, G.; Tsuchiya, T. and Amsel, L.P.: Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man. Clinical Pharmacology and Therapeutics 13: 258–268 (1972).PubMedGoogle Scholar
  75. Levy, G.; Lampman, T.; Kamath, B.L. and Garrettson, L.K.: Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid. New England Journal of Medicine 293: 323–325 (1975).PubMedCrossRefGoogle Scholar
  76. Levy, G.; Baliah, T. and Procknal, J.A.: Effect of renal transplantation on protein binding of drugs in serum of donor and recipient. Clinical Pharmacology and Therapeutics 20: 512–516 (1976).PubMedGoogle Scholar
  77. Lieberman, S.V. and Wood, J.M.: Aspirin formulation and absorption rate. II. Influence on serum levels of tablets, antiacids and solutions. Journal of Pharmaceutical Sciences 53: 1492–1495 (1964).PubMedCrossRefGoogle Scholar
  78. Levy, G.; Procknal, J.A.; Olufs, B.A.R. and Pachman, L.M.: Relationship between serum salicylate concentration and free or total salicylate concentration in serum of children with juvenile rheumatoid arthritis. Clinical Pharmacology and Therapeutics 27: 619–627 (1980).PubMedCrossRefGoogle Scholar
  79. Macpherson, C.R.; Milne, M.D. and Evans, B.M.: The excretion of salicylate. British Journal of Pharmacology 10: 484–489 (1955).Google Scholar
  80. Mäkelä, A.-L.; Yrjänä, T. and Haapasaari, J.: Dosage of salicylates for children with juvenile rheumatoid arthritis. Scandinavian Journal of Rheumatology 4, 250–252 (1975).PubMedCrossRefGoogle Scholar
  81. Mäkelä, A.L.; Yrjänä, T. and Mattila, M.: Dosage of salicylate for children with juvenile rheumatoid arthritis. Acta Paediatrica Scandinavica 68: 423–430 (1979).PubMedCrossRefGoogle Scholar
  82. Miller, R.L. and Melmon, K.L.: Inflammatory disorders; in Morrelli and Melmon (Eds.) Clinical Pharmacology, pp.382–417 (MacMillan, New York 1972).Google Scholar
  83. Miller, R.R.: Deafness due to plain and long acting aspirin tablets. Journal Clinical Pharmacology 18: 468–471 (1978).Google Scholar
  84. Mitchell, I.: ‘Therapeutic’ salicylate poisoning in children. British Medical Journal 1: 1081 (1979).PubMedCrossRefGoogle Scholar
  85. Mongan, E.; Kelly, P.; Nies, K.; Porter, W.W. and Paulus, H.E.: Tinnitus as an indication of therapeutic serum salicylate levels. Journal of American Medical Association 226: 142–145 (1973).CrossRefGoogle Scholar
  86. Muller, F.O.; Thundt, H.K.L. and Muller, D.G.: Pharmacokinetic and pharmacodynamic implications of long-term administration of non steroidal antiinflammatory agents. International Journal of Clinical Pharmacology 15: 397 (1977).Google Scholar
  87. Muni, I.A.; Leeling, J.L.; Helms, R.J.; Johnson, N.; Bare, J.J. and Phillips, B.M.: Improved colorimetric determination of aspirin and salicylic acid concentrations in human plasma. Journal of Pharmaceutical Sciences 67: 289–291 (1978).PubMedCrossRefGoogle Scholar
  88. Nikelly, J.G.: Gas chromatographic determination of acetylsalicylic acid in the blood. Analytical Chemistry 36: 2248–2250 (1964).CrossRefGoogle Scholar
  89. Nowak, M.M., Brundhofer, B. and Gibaldi, M.: Rectal absorption from aspirin suppositories in children and adults. Pediatrics 54: 23–26 (1974).PubMedGoogle Scholar
  90. O’Gorman, T. and Koff, R.S.: Salicylate hepatitis. Gastroenterology 72: 726–8 (1977).PubMedGoogle Scholar
  91. Pachman et al.: Pharmacokinetic monitoring of salicylate therapy in children with juvenile rheumatoid arthritis. Arthritis and Rheumatism 22: 826–831 (1979).PubMedCrossRefGoogle Scholar
  92. Paulus, H.E. and Whitehouse, M.W.: Nonsteroid anti-inflammatory agents. Annual Review of Pharmacology 13: 107–125 (1973).PubMedCrossRefGoogle Scholar
  93. Paulus, H.E.; Siegel, M.; Mongan, E.; Okun, R. and Calabro, J.J.: Variations of serum concentrations and half life of salicylate in patients with rheumatoid arthritis. Arthritis and Rheumatism 14: 527–532 (1971).PubMedCrossRefGoogle Scholar
  94. Peng, G.W.; Gadalla, M.A.F.; Smith, V.; Peng, A. and Chiou, W.L.: Simple and rapid high-pressure liquid chromatographic simultaneous determination of aspirin, salicylic acid, and salicyluric acid in plasma. Journal of Pharmaceutical Sciences 67: 710–712 (1978).PubMedCrossRefGoogle Scholar
  95. Pierce, A.W. Jr.: Salicylate poisoning. Pediatrics 54: 342–347 (1974).PubMedGoogle Scholar
  96. Rance, M.J.; Jordan, B.J. and Nichols, J.D.: A simultaneous determination of acetylsalicylic acid, salicylic acid and salicylamide in plasma by gas liquid chromatography. Journal of Pharmacy and Pharmacology 27: 425–429 (1975).PubMedCrossRefGoogle Scholar
  97. Reynolds, R.C. and Cluff, L.E.: Interaction of serum and sodium salicylate: changes during acute infection and the influence on pharmacological activity. Bulletin of Johns Hopkins Hospital 107: 278–290 (1960).Google Scholar
  98. Richens, A. and Warrington, S.: When should plasma drug levels be monitored? Drugs 17: 488–500 (1979).PubMedCrossRefGoogle Scholar
  99. Routh, J.I.; Shane, N.A.; Arredondo, F.G. and Paul, W.D.: Method for the determination of acetylsalicylic acid in the blood. Clinical Chemistry 13: 734–743 (1967).PubMedGoogle Scholar
  100. Rowland, M. and Riegelman, S.: Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administrations in man. Journal of Pharmaceutical Sciences 57: 1313–1319 (1968).CrossRefGoogle Scholar
  101. Rowland, M.; Riegelman, S.; Harris, P.A.; Sholkoff, S.D. and Eyring, E.J.: Kinetics of acetylsalicylic acid disposition in man. Nature 215: 413–414 (1967).PubMedCrossRefGoogle Scholar
  102. Rowland, M.; Riegelman, S.; Harris, P.A. and Sholkoff, S.D.: Absorption kinetics of aspirin in man following oral administration of an aqueous solution. Journal of Pharmaceutical Sciences 61: 379–385 (1972).PubMedCrossRefGoogle Scholar
  103. Rumble, R.H.; Brooks, P.M. and Roberts, M.S.: Interaction between levamisole and aspirin in man. British Journal of Clinical Pharmacy 7: 631–633 (1979).CrossRefGoogle Scholar
  104. Rumble, R.H.; Brooks, P.M. and Robertz, M.S.: Metabolism of salicylate during chronic aspirin therapy. British Journal of Clinical Pharmacology 9: 41–45 (1980).PubMedCrossRefGoogle Scholar
  105. Salem, S.A.M. and Stevenson, I.H.: Absorption kinetics of aspirin and quinine in elderly subjects. British Journal of Clinical Pharmacology 4: 397P (1977).CrossRefGoogle Scholar
  106. Schachter, D. and Manis, J.G.: Salicylate and salicyl conjugates: fluorimetric estimation, biosynthesis and renal excretion in man. Journal of Clinical Investigation 37: 800–807 (1958).PubMedCrossRefGoogle Scholar
  107. Sholkoff, S.D.; Eyring, E.J.; Rowland, M. and Riegelman, S.: Plasma and synovial fluid concentrations of acetylsalicylic acid in patients with rheumatoid arthritis. Arthritis and Rheumatism 10: 348–351 (1967).PubMedCrossRefGoogle Scholar
  108. Smith, M.J.M.: Plasma-salicylate concentrations after small doses of acetylsalicylic acid. Journal of Pharmacy and Pharmacology 3: 409–414 (1951).PubMedCrossRefGoogle Scholar
  109. Smith, P.K.; Gleason, H.L.; Stoll, C.G. and Ogorzalek, S.: Studies on the pharmacology of salicylates. Journal of Pharmacology and Experimental Therapeutics 87: 237–255 (1946).PubMedGoogle Scholar
  110. Smyth, C.J. and Bravo, J.F.: Antirheumatic drugs: clinical pharmacological and therapeutic aspects. Drugs 10: 394–425 (1975).PubMedCrossRefGoogle Scholar
  111. Soren, A.: Kinetics of salicylates in blood and joint fluids. Journal of Clinical Pharmacology 15: 173–177 (1975).PubMedGoogle Scholar
  112. Spector, R.; Korkin, D.T. and Lorenzo, A.V.: A rapid method for the determination of salicylate binding by the use of ultrafilters. Journal of Pharmacy and Pharmacology 24: 786–789 (1972).PubMedCrossRefGoogle Scholar
  113. Stevenson, G.W.: Rapid ultraviolet spectrophotometric determination of salicylate in blood. Analytical Chemistry 32: 1522–1525 (1960).CrossRefGoogle Scholar
  114. Stevenson, R.L. and Burtis, C.A.: The analysis of aspirin and related compounds by liquid chromatography. Journal of Chromatography 61: 253–261 (1971).PubMedCrossRefGoogle Scholar
  115. Talberl, R.L.; Ludden, T.M. and West, R.E.: Rapid establishment of therapeutic serum concentrations of salicylates. Journal of Clinical Pharmacology 19: 108–112 (1979).Google Scholar
  116. Talbert, R.L.; Ludden, T.M.; Littlefield, L.C. and Reed, W.E.: Development of a loading regimen for aspirin. Current Therapeutic Research 27: 584–594 (1980).Google Scholar
  117. Thomas, B.H.; Solomonraj, G. and Coldwell, B.B.: The estimation of acetylsalicylic acid and salicylate in biological fluids by gas-liquid chromatography. Journal of Pharmacy and Pharmacology 25: 201–204 (1973).PubMedCrossRefGoogle Scholar
  118. Tognoni, G.; Bellantuono, C.; Bonati, M.; D’Incalci, M.; Gerna, M.; Latini, R.; Mandelli, M.; Porro, M.G. and Riva, E.: Clinical relevance of pharmacokinetics. Clinical Pharmacokinetics 5: 105–136 (1980).PubMedCrossRefGoogle Scholar
  119. Tognoni, G.; Lakin, R. and Jusko, W.W. (Eds). Frontiers in Therapeutic Drug Monitoring (Raven Press, 1980).Google Scholar
  120. Trinder, P.: Rapid determination of salicylate in biological fluids. Biochemical Journal 57: 301–303 (1954).PubMedGoogle Scholar
  121. Tsuchiya, T. and Levy, G.: Relationship between dose and plateau levels of drugs eliminated by parallel first-order and capacity-limited kinetics. Journal of Pharmaceutical Sciences 61: 541–544 (1972a).PubMedCrossRefGoogle Scholar
  122. Tsuchiya, T. and Levy, C.: Biotransformation of salicylic acid to its acyl and phenolic glucuronides in man. Journal of Pharmaceutical Sciences 61: 800–801 (1972b).PubMedCrossRefGoogle Scholar
  123. Vesell, E.S.: Relationship between drug distribution and therapeutic effects in man. Annual Review of Pharmacology 14: 249–270 (1974).CrossRefGoogle Scholar
  124. Walter, L.J.; Biggs, D.F. and Coutts, R.T.: Simultaneous GLC estimation of salicylic acid and aspirin in plasma. Journal of Pharmaceutical Sciences 63: 1754–1758 (1974).PubMedCrossRefGoogle Scholar
  125. Watson, J.R.; Crescuolo, P. and Fumi Matsui: Rapid simultaneous determination of salicylic acid and aspirin by GC/I: analysis of synthetic aspirin-salicylic acid mixtures and of single-component aspirin tablets. Journal of Pharmaceutical Sciences 60: 454–458 (1971).PubMedCrossRefGoogle Scholar
  126. Wiegand, R.G. and Sanders, P.C.: Calculation of kinetic constants from blood levels of drugs. Journal of Pharmacology and Experimental Therapeutics 146: 271–275 (1964).PubMedGoogle Scholar
  127. Williams, L.A.; Linn, R.A. and Zak, B.: Differential ultraviolet spectrophotometric determination of serum salicylates. Journal of Laboratory and Clinical Medicine 53: 156–162 (1959).PubMedGoogle Scholar
  128. Wilson, J.T.; Howell, R.L.; Holladay, M.W.; Brilis, G.M.; Chrastil, J.; Watson, J.T. and Taber, D.F.: Gentisuric acid: metabolic formation in animals and identification as a metabolite of aspirin in man. Clinical Pharmacology and Therapeutics 23: 635–643 (1978).PubMedGoogle Scholar
  129. Wolfe, J.D.; Metzger, A.L. and Goldstein, R.C.: Aspirin hepatitis. Annals of Internal Medicine 80: 74–76 (1974).PubMedGoogle Scholar
  130. Wosilait, W.D.: Theoretical analysis of the binding of salicylate by human serum albumin: The relationship between free and bound drug and therapeutic levels. European Journal of Clinical Pharmacology 9: 285–290 (1976).PubMedCrossRefGoogle Scholar
  131. Wurster, D.E. and Kramer, S.F.: Investigation of some factors influencing percutaneous absorption. Journal of Pharmaceutical Sciences 50: 288–293 (1961).PubMedCrossRefGoogle Scholar
  132. Yacobi, A. and Levy, G.: Intraindividual relationship between serum protein binding of drug in normal human subjects, patients with impaired renal function, and rats. Journal of Pharmaceutical Sciences 66: 1285–1288 (1977).PubMedCrossRefGoogle Scholar
  133. Zimmerman, H.J.: Editorial: Aspirin-induced hepatic injury. Annals of Internal Medicine 80: 103–105 (1974).PubMedGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd. 1980

Authors and Affiliations

  • M. Mandelli
    • 1
  • G. Tognoni
    • 1
  1. 1.Istituto di Ricerche Farmacologiche ‘Mario Negri’MilanItaly

Personalised recommendations